IVA vs. PBYI, GALT, VERU, CAPR, ATOS, OGI, OMER, ZVRA, TRVI, and CDT
Should you be buying Inventiva stock or one of its competitors? The main competitors of Inventiva include Puma Biotechnology (PBYI), Galectin Therapeutics (GALT), Veru (VERU), Capricor Therapeutics (CAPR), Atossa Therapeutics (ATOS), Organigram (OGI), Omeros (OMER), Zevra Therapeutics (ZVRA), Trevi Therapeutics (TRVI), and Conduit Pharmaceuticals (CDT). These companies are all part of the "pharmaceutical preparations" industry.
Inventiva (NASDAQ:IVA) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, community ranking, risk and media sentiment.
Puma Biotechnology has higher revenue and earnings than Inventiva.
Puma Biotechnology received 521 more outperform votes than Inventiva when rated by MarketBeat users. However, 80.00% of users gave Inventiva an outperform vote while only 66.54% of users gave Puma Biotechnology an outperform vote.
In the previous week, Inventiva had 1 more articles in the media than Puma Biotechnology. MarketBeat recorded 6 mentions for Inventiva and 5 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.68 beat Inventiva's score of 0.54 indicating that Puma Biotechnology is being referred to more favorably in the news media.
Puma Biotechnology has a net margin of 6.79% compared to Inventiva's net margin of 0.00%. Puma Biotechnology's return on equity of 35.49% beat Inventiva's return on equity.
Inventiva currently has a consensus price target of $17.00, indicating a potential upside of 380.23%. Puma Biotechnology has a consensus price target of $7.00, indicating a potential upside of 74.13%. Given Inventiva's higher probable upside, analysts plainly believe Inventiva is more favorable than Puma Biotechnology.
19.1% of Inventiva shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 32.0% of Inventiva shares are held by insiders. Comparatively, 23.7% of Puma Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Inventiva has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.
Summary
Puma Biotechnology beats Inventiva on 9 of the 15 factors compared between the two stocks.
Get Inventiva News Delivered to You Automatically
Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inventiva Competitors List
Related Companies and Tools
